The Weber Light Letter

By Robert Weber, Founder, Weber Medical Systems

From studies to practice: The latest in tPBM and laser therapy for clinicians.

Photobiomodulation | Research | Clinical Practice

Subscribe: The Weber Light Letter

A Framework for Neuro-Light Therapy

What does it really take to support neurodegenerative conditions with photobiomodulation?

In Episode 3 of the podcast, we outlined a working framework used by leading clinicians integrating light for ALS, Parkinson’s, Alzheimer’s, and autism.

Here are the 4 Pillars of effective brain-directed PBM:

1. Reduce the Load Address infections, metals, mold, and environmental stressors that inflame and dysregulate the brain.
2. Restore Mitochondrial Function Use targeted red/NIR light (e.g., 660–1064 nm) to activate cytochrome c oxidase and restore ATP production in damaged neurons.
3. Modulate Inflammation Apply light and complementary agents (e.g., curcumin, artesunate, poly-MVA) to calm microglial activation and protect tissue.
4. Rewire and Rebuild Combine PBM with regenerative strategies, movement, peptides, cognitive therapy, to promote plasticity and repair.

Takeaway: Light can be the activator, but only when the system is ready. Integration, not isolation, drives results.

🎧 Explore the full conversation in Episode 3 on YouTube, Spotify, or Apple Podcasts.

---

Research Spotlight: Recent Findings to Watch

1064 nm tPBM Eases Traumatic Brain Injury by Modulating Glial Cells

A November 2025 animal study found that daily 12‑minute sessions of 1064 nm transcranial photobiomodulation (PBM) significantly reduced cognitive and emotional deficits in a TBI model. Researchers observed changes in microglial polarization and synaptic markers, pointing toward a deeply modulated neuroinflammatory response. BioMed Central

➡ Clinical takeaway: Deep‑penetrating NIR has tangible effects on brain immune cells—suggesting protocols in neurotrauma and neurodegeneration may benefit from targeting 

glial balance.

Extended tPBM Enhances Motor & Non‑Motor Symptoms in Parkinson’s

a 2025 randomized trial, 8 weeks of head+abdomen PBM improved mobility, balance (TUG test), and anxiety in Parkinson’s patients. Continued treatment showed sustained gains after one year. Gaitway Neurophysio

➡ Clinical takeaway: Long‑term, multi‑site light therapy (not just scalp alone) is emerging as an adjunctive strategy for complex movement disorders, protocol continuity matters.

Together, these studies underscore two themes: penetration depth + systemic targeting. They reinforce what we’re building into clinical protocols with the WeberBrain and associated systems.

Source & credit: By Robert Weber, Founder, Weber Medical Systems